Aquasomes have also shown promise as vaccine carriers. In a 2022 study by Jitendra et al., aquasomes prepared with hydroxyapatite and merozoite surface protein-119 (MSP-119) were shown to possess immunoadjuvant properties. Specifically, the small size and relatively large surface area of the nanoparticles contributed to their strong adsorption efficiency of immunogens, and showed slower antigen release and biodegradability in vitro compared to traditional adjuvants. These properties show promise for increasing the time that immunogens are present in vivo. This could increase the exposure of immunogens to antigen-presenting cells and lymphocytes and thus the immunological function of aquasome-based vaccines. Aquasomes prepared in such a manner were shown to induce significant release of antibodies of the immunoglobulin G class in addition to secretion of pro-inflammatory cytokines when compared to MSP-119 alone or MSP-119 with alum, a commonly used immunoadjuvant. These results indicate that aquasomes show promise as vaccine carriers due to their adjuvanticity and their ability to deliver vaccines to tissues.